CpG-ODN Facilitates Effective Intratracheal Immunization and Recall of Memory against Neoantigen-Expressing Alveolar Cells

• Published in: Frontiers in immunology Vol. 8; p. 1201
• Main Authors: Riehn, Mathias, Cebula, Marcin, Hauser, Hansjörg, Wirth, Dagmar
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29.09.2017
• Subjects: alveolar tract; cytotoxic T cells; immune modulation; Immunology; neoantigen; tolerogenic; neoantigen; tolerogenic; alveolar tract; immune modulation; cytotoxic T cells
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2017.01201

Intrapulmonary immune reactions are impaired by the tolerogenic environment of the lung. This is manifested by the absence of effective endogenous T cell responses upon neoantigen expression. This tolerance is considered to contribute to lung cancer and inefficient immune therapeutic interventions. To investigate the mechanisms contributing to lung tolerance and to overcome these restrictions, we developed a transgenic mouse model with induction of a neoantigen (OVA) exclusively in alveolar type II epithelial cells. This model is characterized by the absence of functional endogenous T cell responses upon OVA neoantigen induction. Standard DNA and protein vaccination protocols resulted in the accumulation of high numbers of antigen-specific CD8 T cells in the lung. However, clearance of antigen-expressing cells was not achieved. To overcome this tolerance, we induced inflammatory conditions by coapplication of the TLR ligands LPS and CpG-ODN during intrapulmonary vaccinations. Both ligands induced high numbers of neoantigen-specific T cells in the lung. However, only coapplication of CpG-ODN was sufficient to establish functional cytotoxic responses resulting in the elimination of neoantigen presenting target cells. Remarkably, CpG-ODN was also crucial for functional memory responses upon re-induction of the neoantigen. The results highlight the need of TLR9 co-stimulation for overcoming tolerization, which might be a key factor for therapeutic interventions.